NewAmsterdam Pharma N.V. (NAMS) vs Precigen (PGEN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Precigen (PGEN) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 136.0% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with +63.4% for PGEN. Precigen is the larger company by market cap ($2.72 billion vs $2.49 billion), about 1.1 times the size.
NewAmsterdam Pharma N.V. converts more of its revenue into profit, with a net margin of -905.7% versus -2588.2%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | PGEN |
|---|---|---|
| Share price | $21.26 | $7.60 |
| Market cap | $2.49B | $2.72B |
| 1-day change | -3.93% | +0.80% |
| YTD return | -39.40% | +81.82% |
| 1-year return | -35.30% | +136.02% |
| 5-year return | +117.16% | +63.44% |
| EPS (TTM) | $-2.08 | $-1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | $9.68M |
| Revenue growth (YoY) | -50.61% | +146.73% |
| Net income (latest FY) | $-203.82M | $-250.64M |
| Operating margin | -1002.90% | -1141.13% |
| Net margin | -905.74% | -2588.21% |
| 52-week high | $42.21 | $8.98 |
| 52-week low | $20.91 | $2.99 |
| Distance from 52-week high | -49.63% | -15.37% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +133.54% | +79.61% |
| Average volume | 1.36M | 5.03M |
| Shares outstanding | 116.90M | 358.04M |
| Employees | 100 | 160 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- PGEN has outperformed NAMS by 171.3 percentage points over the past year.
- NewAmsterdam Pharma N.V. is more profitable, keeping -905.7 cents of every revenue dollar as net income versus -2588.2 cents for Precigen.
- Precigen grew revenue faster in its latest fiscal year (+146.73% vs -50.61%).
- The two companies sit in different sectors: NewAmsterdam Pharma N.V. in Health Care and Precigen in Healthcare.
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Precigen
PGEN stock →Precigen, Inc.,a discovery and clinical-stage biopharmaceutical company, develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases. The company offers therapeutic platforms consisting of AdenoVerse platform, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients.
Healthcare · Biotechnology · 160 employees
NAMS vs PGEN FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Precigen?
Precigen (PGEN) is larger, with a market capitalization of $2.72B compared with $2.49B for NewAmsterdam Pharma N.V. (NAMS).
Which stock has performed better over the past year, NAMS or PGEN?
PGEN returned +136.02% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Precigen in the same industry?
No. NewAmsterdam Pharma N.V. is in the Health Care sector, while Precigen is in Healthcare.